Stockhub

Atara Biotherapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

11 August 2022

4 August 2022

  • curprev 15:5215:52, 4 August 2022‎ Paris talk contribs‎ 1,266 bytes +1,266‎ Created page with "Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-ge..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Atara_Biotherapeutics,_Inc.’